Xspray Pharma
Develops improved cancer drugs (PKIs) using a patented amorphous formulation technology.
XSPRAY | ST
Overview
Corporate Details
- ISIN(s):
- SE0009973563 (+3 more)
- LEI:
- 549300NGRQCNZ3X4L157
- Country:
- Sweden
- Address:
- Scheeles väg 2, 171 65 Solna
- Website:
- https://xspraypharma.com/
- Sector:
- Manufacturing
Description
Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-09-11 16:44 |
Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc™ Patent Liti…
|
English | 45.0 KB | ||
| 2023-08-02 08:00 | Swedish | 700.7 KB | |||
| 2023-08-02 08:00 | English | 704.4 KB | |||
| 2023-07-31 11:40 |
New number of shares and votes in Xspray Pharma
|
English | 41.5 KB | ||
| 2023-07-31 11:40 |
Nytt antal aktier och röster i Xspray Pharma
|
Swedish | 41.4 KB | ||
| 2023-07-11 08:50 |
Xspray Pharma receives request for additional information concerning Dasynoc fr…
|
English | 45.4 KB | ||
| 2023-07-11 08:50 |
Xspray Pharma erhåller begäran om ytterligare information gällande Dasynoc från…
|
Swedish | 45.1 KB | ||
| 2023-06-27 19:40 |
Xspray tillförs cirka 251 MSEK genom en företrädesemission
|
Swedish | 58.1 KB | ||
| 2023-06-27 19:40 |
Xspray raises approximately SEK 251 million through a rights issue
|
English | 58.4 KB | ||
| 2023-05-30 13:30 |
Xspray has published prospectus relating to its previously announced rights iss…
|
English | 55.9 KB | ||
| 2023-05-30 13:30 |
Xspray offentliggör prospekt avseende tidigare offentliggjord företrädesemission
|
Swedish | 56.0 KB | ||
| 2023-05-25 13:25 |
Kommuniké från extra bolagsstämma i Xspray Pharma AB (publ)
|
Swedish | 42.3 KB | ||
| 2023-05-25 13:25 |
Bulletin from the extraordinary general meeting of Xspray Pharma AB (publ)
|
English | 42.5 KB | ||
| 2023-05-16 14:00 |
Bulletin from the 2023 annual general meeting of Xspray Pharma AB (publ)
|
English | 46.6 KB | ||
| 2023-05-16 14:00 |
Kommuniké från Årsstämma 2023 i Xspray Pharma AB (publ)
|
Swedish | 45.1 KB |
Automate Your Workflow. Get a real-time feed of all Xspray Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xspray Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xspray Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-10 | Anders Ekblom | Other | Buy | 168,000 | 4,998,000.00 SEK |
| 2024-06-04 | Ribbskottet AB Anders Bladh | Other | Buy | 1,958 | 145,655.62 SEK |
| 2024-06-03 | Anders Bladh, Ribbskottet | Other | Buy | 3,042 | 225,077.58 SEK |
| 2024-05-29 | Per Andersson | Other | Buy | 51,749 | 489,545.54 SEK |
| 2024-05-27 | Per Andersson | Other | Sell | 9,950 | 687,545.00 SEK |
| 2024-05-16 | Anders Bladh | Other | Buy | 10,000 | 503,500.00 SEK |
| 2024-05-02 | Maris Hartmanis | Other | Other | 2,385 | 95,400.00 SEK |
| 2024-05-02 | Christine Lind | Other | Other | 666 | 26,640.00 SEK |
| 2024-05-02 | Anders Ekblom | Other | Other | 500 | 20,000.00 SEK |
| 2024-03-05 | Robert Molander | Other | Buy | 5,000 | 20,000.00 USD |
Peer Companies
